Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro

Cancer Journal from Scientific American

Volumn 3, Issue 1, 1997, Pages 21-30

  Lyne, John C ^a   Melhem, Mona F ^a   Finley, Gene G ^a   Wen, Duanzhi ^b   Liu, Naili ^b   Deng, David H ^a   Salup, Raoul ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b AMGEN INC   (United States)

^c Division of Urologic Surgery   (United States)

Author keywords

ligand; neu differentiation factor; Prostate cancer; receptor

Indexed keywords

NEU DIFFERENTIATION FACTOR; RECEPTOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL DIVISION; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEUREGULINS; NUCLEIC ACID SYNTHESIS INHIBITORS; PLOIDIES; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TUMOR CELLS, CULTURED;

EID: 0030933521     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Parker SL, Tong T, Bolden S et al. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-28.
2. Peles E, Bacus SS, Koski RA et al. Isolation of the Neu/HER2 stimulatory ligand; a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 1992;69:205-216.
3. erbB2. Science 1992;256: 1205-1210.
4. Sliwkowski MX, Schaefer G, Akita RW et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994;269:14661-14665.
5. Carraway III KL, Cantley LC. A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell 1994;78:5-8.
6. Ware JL, Maygarden SJ, Koontz WW et al. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol 1991;22:254-258.
7. Mellon K, Thompson S, Charlton RG et al. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 1992;147:496499.
8. Kuhn EJ, Kurnot RA, Sesterhenn IA et al. Expression of the c-erbB-2 (HER2/neu) oncoprotein in human prostatic carcinoma. J Urol 1993;150:1427.
9. erb-b2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 1994;86:1140-1145.
10. Wen D, Peles E, Cupples R et al. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 1992;69:559-572.
11. Bologna M, Muzi P, Biordi L et al. Finasteride dose-dependently reduces the proliferation rate of the LNCaP human prostatic cancer cell line in vitro. Urology 1995;45:282-290.
12. Danilenko DM, Ring BD, Lu JZ et al. Neu differentiation factor upregulates epidermal migration and integrin expression in excisional wounds. J Clin Invest 1995;95:842-851.
13. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
14. Katz AE, Olsson CA, Raffo AJ et al. Molecular staging of prostate cancer with the use of enhanced reverse transcriptase-PCR assay. Urology 1994;43:765-775.
15. Sasdivan R, Morgan R, Jennings S et al. Overexpression of HER2/ neu may be an indicator of poor prognosis in prostate cancer. J Urol 1993;150:126-131.
16. Fox SB, Persad RA, Coleman N et al. Prognostic value of c-erbB2 and epidermal growth factor in stage A1 (t1,2) prostatic adenocarcinoma. Br J Urol 1994;74:214-220.
17. Veltri RW, Partin AW, Epstein JE et al. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem Suppl 1994;19:249-258.
18. Orr-Urtreger A, Trakhtenbrot L, Ben-Levy R et al. Neural expression and chromosomal mapping of neu differentiation factor to 8p12-21. Proc Natl Acad Sci USA 1993;90:1867-1871.
19. Emmert-Buck MR, Vocke CD, Pozzatti RO et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995;55:2959-2962.
20. Trapman J, Sleddens HFBM, van der Weiden MM et al. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8s87 and D8s133 in human prostate cancer. Cancer Res 1994;54:6061-6064.
21. Bova GS, Carter BS, Bussemakers MJG et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53:3869-3873.
22. Ichikawa T, Nihei N, Suzuki H et al. Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res 1994;54:2299-2302.
23. Qiu SD, Young CYF, Bilhartz DL et al. In situ hybridization of prostate specific antigen mRNA in human prostate. J Urol 1990; 144:1550-1556.
24. Partin AW, Carter HB, Chan DW et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143:747-752.
25. Veldscholte J, Ris-Stalpers C, Kuiper GGJM et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;17:534-540.
26. Lee SE, Currin SM, Paulson DF et al. Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesical involvement and histopathological grading is a predictor of clinical outcome. J Urol 1988;140:769-774.
27. Veltri RW, Miller MC, Marley GM et al. Abnormal expression of a truncated intracellular HER-2/neu mRNA in prostate cancer. Proceedings of the AACR 1996;37:572-582.
28. Zincke H, Utz DC, Thule PM et al. Treatment options for patients with stage D1 (T0-3, N1-2, Mo) adenocarcinoma of prostate. Urology 1987;30:307-315.
29. Zincke H. Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate: significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology 1989;23(suppl):27-36.
30. Fordham MVP, Burdge AH, Matthews J et al. Prostatic carcinoma cell DNA content measured by flow cytometry and its relation to clinical outcome. Br J Surg 1986;73:400-403.
31. Frankfurt OS, Chin CL, Englander LS et al. Relationship between DNA ploidy, glandular differentiation, and tumor spread in human prostate cancer. Cancer Res 1985;45:1418-1423.
32. McNeal JE, Villers AA, Redwine EA et al. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990;66:1225-1233.
33. Tavares AS, Costa J, Costa Maia J. Correlation between ploidy and prognosis in prostatic carcinoma. J Urol 1973;109:676-679.
34. Epstein JI, Pizov G, Walsh PC. Correlation of pathological findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-3593.
35. Hanks GE. External beam radiation therapy for prostate cancer: still the gold standard. Oncology (Huntingt) 1992;6:79-86, 89-94.
36. Partin AW, Piantadosi S, Sanda MG et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45:831-838.
37. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-248.
38. Avis G, Hugosson J, Norlen L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995; 154:460-465.
39. Blackard CE, Byar DP, Jordan WP Jr. Veterans Administration Cooperative Urological Research Group: orchiectomy for advanced carcinoma: a reevaluation. Urology 1973;1:553-557.